• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by VolitionRX Limited

    7/24/24 4:06:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VNRX alert in real time by email
    S-8 1 vnrx_s8.htm REGISTRATION STATEMENT ON FORM S-8 vnrx_s8.htm

     

    As filed with the Securities and Exchange Commission on July 24, 2024

     

    Registration No. 333-____________

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    VOLITIONRX LIMITED

    (Exact name of registrant as specified in its charter)

     

    Delaware

    91-1949078

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     

    1489 West Warm Springs Road, Suite 110

    Henderson, Nevada

     

    89014

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    VolitionRx 2024 Stock Incentive Plan

    (Full title of the plan)

     

    Agents and Corporations, Inc.

    1201 Orange Street, Suite 600

    Wilmington, Delaware 19801

    (Name and address of agent for service)

     

    +1 (302) 575-0877

    (Telephone number, including area code, of agent for service)

     

    Copy to:

    Marc G. Alcser

    Stradling Yocca Carlson & Rauth LLP

    660 Newport Center Drive, Suite 1600

    Newport Beach, California 92660

    (949) 725-4000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the VolitionRx Limited 2024 Stock Incentive Plan, as specified by Rule 428(b)(1) under the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.Incorporation of Documents by Reference

     

    The following documents, which have been filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference herein, and shall be deemed to be part of, this Registration Statement:

     

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 25, 2024;

     

     

     

     

    (b)

    The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the Commission on May 13, 2024;

     

     

     

     

    (c)

    The Registrant’s Current Reports on Form 8-K, filed with the Commission on January 2, 2024, March 19, 2024, April 26, 2024, and July 3, 2024, respectively (to the extent that such information is filed and not furnished); and

     

     

     

     

    (d)

    The description of the Registrant’s common stock which is contained in the Registration Statement on Form 8-A, filed with the Commission on February 3, 2015 (File No. 001-36833) pursuant to Section 12(b) of the Exchange Act, Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Commission on February 20, 2020, and any other amendments or reports filed for the purpose of updating such description.

     

     
    2

     

     

    In addition, all other documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, subsequent to the date of the filing of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities registered hereunder have been sold, or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual, quarterly or current report or other document, or any portion thereof, that is deemed “furnished” and not deemed “filed” in accordance with applicable Commission rules. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Under no circumstances will any information filed under Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such Form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides for the contrary.

     

    The documents incorporated by reference herein contain or will contain forward-looking statements that involve risks and uncertainties. The Registrant’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, the risks identified in the respective documents incorporated by reference.

     

    Item 4. Description of Securities

     

    Not Applicable.

     

    Item 5. Interests of Named Experts and Counsel

     

    Not Applicable.

     

    Item 6. Indemnification of Directors and Officers

     

    The Registrant is incorporated under the laws of the State of Delaware. Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”) permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:

     

     

    ·

    breach of a director’s duty of loyalty to the corporation or its stockholders;

     

     

     

     

    ·

    act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

     

     

     

    ·

    unlawful payment of dividends or redemption of shares (DGCL Section 174); or

     

     

     

     

    ·

    transaction from which the director derives an improper personal benefit.

     

    Section 145 of the DGCL provides, in general, that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than a derivative action by or in the right of the corporation), by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. In the case of a derivative action, a Delaware corporation may indemnify any such person against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification will be made in respect of any claim, issue or matter as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or any other court in which such action was brought determines such person is fairly and reasonably entitled to indemnity for such expenses. To the extent that a present or former director or officer of a Delaware corporation is successful on the merits or otherwise in defense of any action, suit or proceeding referred to above, or in defense of any claim, issue or matter therein, Section 145 of the DGCL provides that such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with such action, suit or proceeding.

     

     
    3

     

     

    Section 174 of the DGCL provides, among other things, that a director, who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful actions were approved or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

     

    Regarding indemnification for liabilities arising under the Securities Act which may be permitted for directors or officers pursuant to the foregoing provisions, the Registrant is informed that, in the opinion of the Commission, such indemnification is against public policy, as expressed in the Securities Act and is therefore unenforceable.

     

    The Registrant’s Second Amended and Restated Certificate of Incorporation, as amended, authorizes it to, and its Amended and Restated Bylaws, as amended, provide that it shall, indemnify its directors and officers to the fullest extent permitted by the DGCL and also pay expenses incurred in defending any such proceeding in advance of its final disposition upon delivery of an undertaking, by or on behalf of an indemnified person, to repay all amounts so advanced if it should be determined ultimately that such person is not entitled to be indemnified under the bylaws or the DGCL.

     

    As permitted by the DGCL, the Registrant has entered into indemnification agreements with each of its directors and certain of its officers. These agreements require it to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to the Registrant, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.

     

    The Registrant has an insurance policy covering its officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act, or otherwise.

     

    Item 7. Exemption from Registration Claimed

     

    Not Applicable.

     

    Item 8.Exhibits

     

    A list of exhibits filed with this Registration Statement is set forth in the Exhibit Index and is incorporated herein by reference.

     

     
    4

     

     

    Item 9. Undertakings

     

     

    (a)

    The undersigned Registrant hereby undertakes:

     

     

    (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

     

    (i)

    to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

     

     

     

    (ii)

    to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of the securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b), if in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in Exhibit 107 (Filing Fee Table) to the effective registration statement; and

     

     

     

     

    (iii)

    to include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

     

    provided, however, that: paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

     

    (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time will be deemed to be the initial bona fide offering thereof.

     

     

     

     

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

     

    (b)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

     

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     
    5

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Dubai, United Arab Emirates, on July 24, 2024.

     

     

    VOLITIONRX LIMITED

     

     

     

     

    By:

    /s/ Cameron Reynolds 

     

     

    Cameron Reynolds

     

     

     

    President and Chief Executive Officer

     

     

     

    (Authorized Signatory and Principal Executive Officer)

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Cameron Reynolds and Rodney Rootsaert, and each of them, acting individually, his or her true and lawful attorneys-in-fact and agent with full power of substitution and re-substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Cameron Reynolds

     

    President, Chief Executive Officer and Director

     

    July 24, 2024

    Cameron Reynolds

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Terig Hughes

     

    Chief Financial Officer and Treasurer

     

    July 24, 2024

    Terig Hughes

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

    /s/ Rodney Gerard Rootsaert

     

    Secretary

     

    July 24, 2024

    Rodney Gerard Rootsaert

     

     

     

     

     

     

     

     

     

    /s/ Guy Innes

     

    Director

     

    July 24, 2024

    Guy Innes

     

     

     

     

     

     

     

     

     

    /s/ Dr. Alan Colman

     

    Director

     

    July 24, 2024

    Dr. Alan Colman

     

     

     

     

     

     

     

     

     

    /s/ Dr. Phillip Barnes

     

    Director

     

    July 24, 2024

    Dr. Phillip Barnes

     

     

     

     

     

     

     

     

     

    /s/ Kim Nguyen

     

    Director

     

    July 24, 2024

    Kim Nguyen

     

     

     

     

     

     

     

     

     

    /s/ Mickie Henshall

     

    Director

     

    July 24, 2024

    Mickie Henshall

     

     

     

     

     

     
    6

     

     

    EXHIBIT INDEX

     

     

     

     

     

    Incorporated by Reference

     

    Exhibit

    Number

     

    Exhibit Description

     

    Form

     

    File No.

     

    Exhibit

     

    Filing Date

     

    Filed

    Herewith

    4.1

     

    Specimen Common Stock Certificate.

     

    10-SB

     

    000-30402

     

    3(A)

     

    12/6/99

     

     

    4.2

     

    Second Amended and Restated Certificate of Incorporation, as amended.

     

     

     

     

     

     

     

     

     

    X

    4.3

     

    Amended and Restated Bylaws, as amended.

     

    10-Q

     

    001-36833

     

    3.2

     

    5/13/24

     

     

    5.1

     

    Opinion of Stradling Yocca Carlson & Rauth LLP.

     

     

     

     

     

     

     

     

     

    X

    23.1

     

    Consent of Stradling Yocca Carlson & Rauth LLP (contained in Exhibit 5.1).

     

     

     

     

     

     

     

     

     

    X

    23.2

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

     

     

    X

    24.1

     

    Power of Attorney (contained on signature page).

     

     

     

     

     

     

     

     

     

    X

    99.1#

     

    2024 Stock Incentive Plan.

     

    8-K

     

    001-36833

     

    10.1

     

    07/3/24

     

     

    99.1(a)#

     

    Form of Notice of Stock Option Grant and Stock Option Agreement under the 2024 Stock Incentive Plan.

     

     

     

     

     

     

     

     

     

    X

    99.1(b)#

     

    Form of Notice of Performance Shares Award and Performance Shares Agreement under the 2024 Stock Incentive Plan.

     

     

     

     

     

     

     

     

     

    X

    99.1(c)#

     

    Form of Notice of Restricted Stock Award and Restricted Stock Agreement under the 2024 Stock Incentive Plan.

     

     

     

     

     

     

     

     

     

    X

    99.1(d)#

     

    Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the 2024 Stock Incentive Plan.

     

     

     

     

     

     

     

     

     

    X

    99.1(e)#

     

    Form of Notice of Stock Appreciation Right Award and Stock Appreciation Right Award Agreement under the 2024 Stock Incentive Plan.

     

     

     

     

     

     

     

     

     

    X

    99.1(f)#

     

    Form of Notice of Stock Bonus Award and Stock Bonus Award Agreement under the 2024 Stock Incentive Plan.

     

     

     

     

     

     

     

     

     

    X

    107

     

    Filing Fee Table.

     

     

     

     

     

     

     

     

     

    X

     

    # Indicates a management contract or compensatory plan or arrangement.

     

     
    7

     

    Get the next $VNRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VNRX

    DatePrice TargetRatingAnalyst
    4/8/2025$2.50Buy
    H.C. Wainwright
    2/1/2023Buy → Hold
    The Benchmark Company
    2/17/2022$8.00 → $7.00Overweight
    Cantor Fitzgerald
    11/16/2021$10.00 → $9.00Buy
    Aegis Capital
    More analyst ratings

    $VNRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

     Showing New Indication for Nu.Q® NETs  HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference in Malta on 5th February.  The session entitled "Empowering Precision‑medicine approach through NETs Plasma Biomarker‑driven personalized treatment"  will be presented by Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, at the 4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece. Professor Evangelos J. Giamarellos-Bourboulis commented: "The scientific program at the EHSF

    2/4/26 8:45:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

    HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL. Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented:"We are keen to support the submission of Volitio

    1/30/26 8:50:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

    Nu.Q® Biomarker Paper Available on MedRXIV HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS), a lifelong disease which affects approximately 1% of the world's population[1].  The Nu.Q® NETs assay is CE-Marked to detect diseases associated with NETosis and is therefore approved and commercially available for clinical use in 27 European Union (EU) member states, the three European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway) an

    1/27/26 8:00:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Reynolds Cameron John bought $7,000 worth of shares (20,000 units at $0.35), increasing direct ownership by 0.79% to 2,554,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/17/25 1:12:19 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Reynolds Cameron John bought $56,100 worth of shares (110,000 units at $0.51), increasing direct ownership by 5% to 2,534,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Innes Guy Archibald bought $49,038 worth of shares (96,153 units at $0.51), increasing direct ownership by 10% to 1,062,967 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:33 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    SEC Filings

    View All

    Amendment: SEC Form D/A filed by VolitionRX Limited

    D/A - VOLITIONRX LTD (0000093314) (Filer)

    1/28/26 2:09:57 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form PRE 14A filed by VolitionRX Limited

    PRE 14A - VOLITIONRX LTD (0000093314) (Filer)

    1/26/26 5:20:07 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    1/8/26 5:28:57 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on VolitionRx with a new price target

    H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

    4/8/25 8:02:28 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx downgraded by The Benchmark Company

    The Benchmark Company downgraded VolitionRx from Buy to Hold

    2/1/23 7:40:33 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cantor Fitzgerald resumed coverage on VolitionRx with a new price target

    Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously

    2/17/22 9:10:02 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Forterre Gael covered exercise/tax liability with 2,010 shares, decreasing direct ownership by 1% to 189,872 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    2/3/26 4:05:22 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Secretary Rootsaert Rodney Gerard covered exercise/tax liability with 3,196 shares, decreasing direct ownership by 2% to 162,262 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    2/3/26 4:05:11 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    GC - Volition Diagnostics Plummer Nicholas covered exercise/tax liability with 5,647 shares, decreasing direct ownership by 2% to 233,137 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    2/3/26 4:05:05 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Financials

    Live finance-specific insights

    View All

    VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Third Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, November 14, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800

    11/10/25 8:45:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, August 15, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 34

    8/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

    5/15/25 5:37:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 4:05:14 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 3:40:04 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by VolitionRX Limited (Amendment)

    SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)

    2/14/24 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Leadership Updates

    Live Leadership Updates

    View All

    Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

    HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal diseas

    1/20/26 8:25:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Issues Business Review 2024

    HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

    1/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Appoints Timothy I. Still as Chairman

    HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development

    11/6/24 4:10:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care